These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2669402)

  • 21. Influence of bosentan on fingertip rewarming in patients with systemic sclerosis.
    Autenrieth J; Riemekasten G; Bert C; Worm M
    J Dtsch Dermatol Ges; 2013 Apr; 11(4):356-9. PubMed ID: 23419126
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.
    Martin MF; Dowd PM; Ring EF; Cooke ED; Dieppe PA; Kirby JD
    Ann Rheum Dis; 1981 Aug; 40(4):350-4. PubMed ID: 7259326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sympatholytic effect of intra-arterial reserpine in sclerodermia and Raynaud's disease].
    Acevedo A; Palacios JM; López R; Palma F
    Rev Med Chil; 1984 Jun; 112(6):553-8. PubMed ID: 6515168
    [No Abstract]   [Full Text] [Related]  

  • 29. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
    Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
    Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon.
    Anderson ME; Moore TL; Lunt M; Herrick AL
    Rheumatology (Oxford); 2007 Mar; 46(3):533-8. PubMed ID: 17018538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)].
    Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S
    Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight dextran in systemic sclerosis and Raynaud's phenomenon.
    Dodman B; Rowell NR
    Acta Derm Venereol; 1982; 62(5):440-2. PubMed ID: 6183899
    [No Abstract]   [Full Text] [Related]  

  • 34. Plethysmographical and clinical observations on Bricanyl therapy in Raynaud's phenomenon.
    Zabel J; Fyrand O; Thune P
    Acta Derm Venereol; 1974; 54(5):391-5. PubMed ID: 4138501
    [No Abstract]   [Full Text] [Related]  

  • 35. [Griseofulvin administered for an indeterminate time in the therapy of systemic scleroderma and Raynaud's syndrome].
    Giordano M; Capelli L; Ara M; Tirri G
    Reumatismo; 1971; 23(2):82-92. PubMed ID: 5146109
    [No Abstract]   [Full Text] [Related]  

  • 36. [Diagnosis and clinical relevance of microcirculation disorders in progressive scleroderma].
    Brenke A; Brenke R; Loreck D
    Dermatol Monatsschr; 1990; 176(1):27-33. PubMed ID: 2311789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
    McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ
    Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laser-Doppler measurement of digital blood flow regulation in normals and in patients with Raynaud's phenomenon.
    Kristensen JK; Engelhart M; Nielsen T
    Acta Derm Venereol; 1983; 63(1):43-7. PubMed ID: 6191488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intra-arterial reserpine for Raynaud's syndrome. Systemic reactions without therapeutic benefit.
    Surwit RS; Gilgor RS; Duvic M; Allen LM; Neal JA
    Arch Dermatol; 1983 Sep; 119(9):733-5. PubMed ID: 6614959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
    Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG
    J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.